Chronic hepatitis in man and in dog: a comparative update

Cerquetella, Matteo; Giuliano, Vittorio; Rossi, Giacomo; Corsi, Simona; Laus, Fulvio; Spaterna, Andrea; Villanacci, Vincenzo; Bassotti, Gabrio

doi:10.4321/s1130-01082012000400006

Cited by 6 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progressive replacement of hepatocytes with fibrous tissue is another consequence of chronic hepatic disease, which can result in hepatic synthetic failure. If this develops, coagulopathies may occur . Dogs with liver disease traditionally were thought to be hypocoagulable because they can have prolonged clotting times (prothrombin and activated partial thromboplastin times), hypofibrinogenemia, and mild‐to‐moderate thrombocytopenia .…”

Section: Consequences Of Hepatic Fibrosismentioning

confidence: 99%

“…If this develops, coagulopathies may occur. 115 Dogs with liver disease traditionally were thought to be hypocoagulable because they can have prolonged clotting times (prothrombin and activated partial thromboplastin times), hypofibrinogenemia, and mild-to-moderate thrombocytopenia. 83,116,117 Despite this, spontaneous bleeding is rare.…”

Section: Consequences Of Hepatic Fibrosismentioning

confidence: 99%

See 1 more Smart Citation

Hepatic Fibrosis in Dogs

Eulenberg

Lidbury

2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

Hepatic fibrosis is commonly diagnosed in dogs, often as a sequela to chronic hepatitis (CH). The development of fibrosis is a crucial event in the progression of hepatic disease that is of prognostic value. The pathophysiology of hepatic fibrosis in human patients and rodent models has been studied extensively. Although less is known about this process in dogs, evidence suggests that fibrogenic mechanisms are similar between species and that activation of hepatic stellate cells is a key step. Diagnosis and staging of hepatic fibrosis in dogs requires histopathological examination of a liver biopsy specimen. However, performing a liver biopsy is invasive and assessment of fibrotic stage is complicated by the absence of a universally accepted staging scheme in veterinary medicine. Serum biomarkers that can discriminate among different fibrosis stages are used in human patients, but such markers must be more completely evaluated in dogs before clinical use. When successful treatment of its underlying cause is feasible, reversal of hepatic fibrosis has been shown to be possible in rodent models and human patients. Reversal of fibrosis has not been well documented in dogs, but successful treatment of CH is possible. In human medicine, better understanding of the pathomechanisms of hepatic fibrosis is leading to the development of novel treatment strategies. In time, these may be applied to dogs. This article comparatively reviews the pathogenesis of hepatic fibrosis, its diagnosis, and its treatment in dogs.

show abstract

Section: Consequences Of Hepatic Fibrosismentioning

confidence: 99%

Section: Consequences Of Hepatic Fibrosismentioning

confidence: 99%

Hepatic Fibrosis in Dogs

Eulenberg

Lidbury

2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…In addition, there are many acquired acute and chronic hepatic diseases in humans and animals related to infectious, inflammatory, degenerative, vascular, neoplastic, drug- or toxin-related processes, as well as hepatopathies of idiopathic origin, which are associated with high serum liver enzyme activities 10 – 13 . Of major human public health concerns are acute and chronic hepatitis virus A to E infections and alcohol-related liver diseases 14 , which are not recognized in dogs 15 . However, viral hepatopathy in dogs can be induced by canine hepatitis adenovirus type 1, although this is now exceedingly rare due to general vaccination strategies 16 .…”

Section: Introductionmentioning

confidence: 99%

Metabolomic serum abnormalities in dogs with hepatopathies

Imbery

Dieterle

Ottka

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Hepatopathies can cause major metabolic abnormalities in humans and animals. This study examined differences in serum metabolomic parameters and patterns in left-over serum samples from dogs with either congenital portosystemic shunts (cPSS, n = 24) or high serum liver enzyme activities (HLEA, n = 25) compared to control dogs (n = 64). A validated targeted proton nuclear magnetic resonance spectroscopy platform was used to assess 123 parameters. Principal component analysis of the serum metabolome demonstrated distinct clustering among individuals in each group, with the cluster of HLEA being broader compared to the other groups, presumably due to the wider spectrum of hepatic diseases represented in these samples. While younger and older adult control dogs had very similar metabolomic patterns and clusters, there were changes in many metabolites in the hepatopathy groups. Higher phenylalanine and tyrosine concentrations, lower branched-chained amino acids (BCAAs) concentrations, and altered fatty acid parameters were seen in cPSS dogs compared to controls. In contrast, dogs with HLEA had increased concentrations of BCAAs, phenylalanine, and various lipoproteins. Machine learning based solely on the metabolomics data showed excellent group classification, potentially identifying a novel tool to differentiate hepatopathies. The observed changes in metabolic parameters could provide invaluable insight into the pathophysiology, diagnosis, and prognosis of hepatopathies.

show abstract

“…Acute and chronic hepatobiliary diseases are quite commonly reported in both dogs and cats [1][2][3]. ese conditions recognize many different causes, as well as numerous therapeutic options also depending on several aspects such as underlying cause, chronicity, species involved, and others.…”

Section: Introductionmentioning

confidence: 99%

Evidences on Molecules Most Frequently Included in Canine and Feline Complementary Feed to Support Liver Function

Marchegiani

Fruganti

Gavazza

et al. 2020

Veterinary Medicine International

Self Cite

View full text Add to dashboard Cite

Numerous complementary feeds to support liver function are commercially available for small animals. Aiming to furnish a scientific support for clinicians/nutritionists that necessitate a complementary feed to support liver function in dogs and cats, with the present paper, we analyzed scientific evidences supporting the use, for this purpose, of ingredients/additives such as artichoke (Cynara scolymus), curcumin, dandelion (Taraxacum officinale), milk thistle (Silybum marianum), phosphatidylcholine, and S-adenosylmethionine. Although sustained by significant results, our review found only few scientific papers, and albeit we believe that they represent a significant aid in handling hepatopathies, in the authors’ opinion, this topic probably deserves, and would benefit of, further studies.

show abstract

Chronic hepatitis in man and in dog: a comparative update

Cited by 6 publications

References 48 publications

Hepatic Fibrosis in Dogs

Hepatic Fibrosis in Dogs

Metabolomic serum abnormalities in dogs with hepatopathies

Evidences on Molecules Most Frequently Included in Canine and Feline Complementary Feed to Support Liver Function

Contact Info

Product

Resources

About